Vivatlac in Irritable Bowel Syndrome II (ViIBS2)
Key facts
- Where
- Jarocin, PolandSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07235215, who can take part
Where in Poland
- District Hospital JarocinJarocin, PolandContact: Jacek Piatek, Prof. MD. PhD.Taking people
- GP Clinic SpitalnaJarocin, PolandContact: Pawel Olszewski, Dr.Taking people
- GP Clinic WroclawskaJarocin, PolandContact: Krystian Andrzejczak, Dr.Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz
- Trial code
- NCT07235215
- Record updated
- 15 December 2025
- Original description
Multi-center,randomized, double-blind, placebo-controlled, 36 weeks trial investigating the effects of a nine-strain synbiotic (Vivatlac Synbiotikum) in IBS patientsRead full original descriptionShow less
Effects of Vivatlac Synbiotic in Patients With Irritable Bowel Syndrome - A Randomized, Double-blind, Placebo-Controlled, 36 Weeks Clinical Trial
Multi-center,randomized, double-blind, placebo-controlled, 36 weeks trial investigating the effects of a nine-strain synbiotic (Vivatlac Synbiotikum) in IBS patients
Inclusion: diagnosed for Irritable Bowel Syndrome using the IBS questionnaire for Health Care Providers of the World Global Gastroenterology Organization; IBS-SSS ≥ 175 points.
Exclusion: patients currently taking products containing probiotics or have taken this kind of products during the last 3 months; patients currently taking antibiotics or have taken antibiotics during the last 3 months; patients having a concurrent severe illness (malignancies, uncontrolled hypertension or diabetes, hepatic, renal or cardiac dysfunctions, serious neurological disorders, psychosis, respiratory disorders such as asthma or COPD, hyper- or hypothyroidism; patients using motility drugs or dietary fiber supplements withing 2 weeks before study start; patient taking anti-coagulant medication; patients having chronic bowel disorders other than IBS, including inflammatory bowel disease, gastroenteritis, stomach and duodenal cancer, celiac disease; patient being pregnant, lactating, or planning to become pregnant during the next 9 months; patient being diagnosed to have a lactose intolerance; patients have participated in another clinical trial within the last three months.